CCL5 and neoplasm: Previous studies have shown that engineering OAd (Ad5-ZD55-CCL5-IL12), which co-express CCL5 and IL-12, effectively increased the infiltration of chimeric antigen receptor (CAR)-T cells and TILs within tumors, resulting in potent anti-tumor effects with enhanced safety profiles (28).